InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,463.54
(
0.08%
)
US TECH 100
18,480.00
(
-0.21%
)
Dow Jones
40,539.93
(
-0.12%
)
Brent Oil
78.64
(
-0.64%
)
Bitcoin
66,798.86
(
-0.04%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Whosetosay

Send PM Follow Ignore
Followers 26
Posts 4429
Boards Moderated 0
Alias Born 06/08/2010

Whosetosay

Re: nyctraydr post# 71146

Thursday, 02/04/2016 1:31:16 PM

Thursday, February 04, 2016 1:31:16 PM

Post# of 80490
Keytruda and Optivo have around $500M in sales in 2015. Add Xalkori for $500M, that $1B. Pfizer sees Xalkori at $1B in 2020. This analyst saw $8.8B in 2018.

He likely added EGFR to the mix. '113 is useless against EGFR, although Ariad had touted it as effective early on.

We'll be 3rd or 4th to the party, including againg a PD-1 competitor.

'113 should generate healthy sales, but this article is misleading as to the market/dynamics.

The BoD overpaid themselves and the CEO, they breached their fiduciary responsibilities, they doctored their records and coerced and bought off their accuser...I want THE TRUTH!!!

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up